Roswitha Kammler

Bern, BE, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 12, 2026

Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial.

Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 22, 2026

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 22, 2026

Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.

Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.

Journal: Breast (Edinburgh, Scotland)

Published: November 21, 2025

Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.

Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.

Journal: The Lancet. Oncology

Published: November 17, 2025

Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project.

Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 04, 2025

Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index.

Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index.

Journal: JAMA network open

Published: November 03, 2025

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 26, 2025

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 26, 2025

Corrigendum to "Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial" [The Breast 83 (2025) 104547].

Corrigendum to "Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial" [The Breast 83 (2025) 104547].

Journal: Breast (Edinburgh, Scotland)

Published: September 23, 2025

Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).

Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 05, 2025

Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial.

Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial.

Journal: Breast (Edinburgh, Scotland)

Published: May 18, 2025

Showing 1-12 of 57

Last Updated: 09/26/2026